JP2007520440A5 - - Google Patents

Download PDF

Info

Publication number
JP2007520440A5
JP2007520440A5 JP2006518649A JP2006518649A JP2007520440A5 JP 2007520440 A5 JP2007520440 A5 JP 2007520440A5 JP 2006518649 A JP2006518649 A JP 2006518649A JP 2006518649 A JP2006518649 A JP 2006518649A JP 2007520440 A5 JP2007520440 A5 JP 2007520440A5
Authority
JP
Japan
Prior art keywords
group
alkyl
alkoxy
halogen
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006518649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520440A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/019094 external-priority patent/WO2005009941A1/en
Publication of JP2007520440A publication Critical patent/JP2007520440A/ja
Publication of JP2007520440A5 publication Critical patent/JP2007520440A5/ja
Pending legal-status Critical Current

Links

JP2006518649A 2003-07-03 2004-06-23 ムスカリン性受容体アゴニストとしてのインダン誘導体 Pending JP2007520440A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48469603P 2003-07-03 2003-07-03
PCT/US2004/019094 WO2005009941A1 (en) 2003-07-03 2004-06-23 Indane derivates as muscarinic receptor agonists

Publications (2)

Publication Number Publication Date
JP2007520440A JP2007520440A (ja) 2007-07-26
JP2007520440A5 true JP2007520440A5 (US06894165-20050517-C00155.png) 2007-09-06

Family

ID=34102660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006518649A Pending JP2007520440A (ja) 2003-07-03 2004-06-23 ムスカリン性受容体アゴニストとしてのインダン誘導体

Country Status (8)

Country Link
US (1) US7265246B2 (US06894165-20050517-C00155.png)
EP (1) EP1644320B1 (US06894165-20050517-C00155.png)
JP (1) JP2007520440A (US06894165-20050517-C00155.png)
AT (1) ATE384039T1 (US06894165-20050517-C00155.png)
CA (1) CA2529036A1 (US06894165-20050517-C00155.png)
DE (1) DE602004011348T2 (US06894165-20050517-C00155.png)
ES (1) ES2298819T3 (US06894165-20050517-C00155.png)
WO (1) WO2005009941A1 (US06894165-20050517-C00155.png)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1819846A (zh) * 2004-05-21 2006-08-16 千寿制药株式会社 包含毒蕈碱性受体激动剂的经皮肤吸收的眼用制剂
CA2634999A1 (en) * 2005-12-27 2007-07-05 University Of Toledo Muscarinic agonists and methods of use thereof
EP2296471A4 (en) 2008-05-15 2012-03-14 Univ Toledo MUSCARIC ACID AGONISTS AS COGNITIVE ENHANCERS
EP2361242B1 (en) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
AU2010233917B2 (en) 2009-04-02 2015-07-02 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
WO2010141690A2 (en) * 2009-06-04 2010-12-09 Dara Biosciences, Inc. Indane analogs and use as pharmaceutical agents and process of making
EP2480528B1 (en) 2009-09-25 2018-08-29 Oryzon Genomics, S.A. Lysine specific demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
MX2012012111A (es) 2010-04-19 2013-05-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especifica de lisina y su uso.
JP5996532B2 (ja) 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 有害生物防除剤としての新規複素環式化合物
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
JP6054868B2 (ja) 2010-07-29 2016-12-27 オリゾン・ジェノミックス・ソシエダッド・アノニマOryzon Genomics S.A. Lsd1のアリールシクロプロピルアミンをベースとしたデメチラーゼ阻害剤およびそれらの医学的使用
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2012149524A1 (en) 2011-04-29 2012-11-01 The University Of Toledo Muscarinic agonists as enhancers of working memory and cognitive flexibility
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
CN104203914B (zh) 2011-10-20 2017-07-11 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
AU2016341884B2 (en) 2015-10-19 2021-06-10 Board Of Regents, The University Of Texas System Piperazinyl norbenzomorphan compounds and methods for using the same
US10653681B2 (en) 2016-03-16 2020-05-19 Recurium Ip Holdings, Llc Analgesic compounds
EP3448520A4 (en) * 2016-04-29 2020-07-29 Board Of Regents, The University Of Texas System SIGMA RECEIVER BINDERS
EP3448519A4 (en) * 2016-04-29 2020-01-22 Board Of Regents, The University Of Texas System SIGMA RECEIVER BINDERS
CN114736128A (zh) * 2022-03-10 2022-07-12 青岛科技大学 一种制备邻氨基苯醚的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025983A1 (en) 1996-01-22 1997-07-24 Eli Lilly And Company Indane derivatives for antipsychotic compositions
JP2001510797A (ja) 1997-07-22 2001-08-07 イーライ・リリー・アンド・カンパニー 医薬化合物
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
KR20040053130A (ko) * 2001-09-21 2004-06-23 일라이 릴리 앤드 캄파니 무스카린성 효능제

Similar Documents

Publication Publication Date Title
JP2007520440A5 (US06894165-20050517-C00155.png)
JP2002030084A5 (US06894165-20050517-C00155.png)
JP2004517087A5 (US06894165-20050517-C00155.png)
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
JP2017533968A5 (US06894165-20050517-C00155.png)
JP2005535586A5 (US06894165-20050517-C00155.png)
JP2006524222A5 (US06894165-20050517-C00155.png)
TW200607807A (en) Macrocyclic beta-secretase inhibitors
JP2007538031A5 (US06894165-20050517-C00155.png)
JP2009501745A5 (US06894165-20050517-C00155.png)
RU2007116987A (ru) Новые соединения
JP2009536620A5 (US06894165-20050517-C00155.png)
JP2011519854A5 (US06894165-20050517-C00155.png)
JP2005530811A5 (US06894165-20050517-C00155.png)
JP2010501478A5 (US06894165-20050517-C00155.png)
JP2006501201A5 (US06894165-20050517-C00155.png)
JP2005511547A5 (US06894165-20050517-C00155.png)
JP2002527414A5 (US06894165-20050517-C00155.png)
JP2005527542A5 (US06894165-20050517-C00155.png)
JP2007504235A5 (US06894165-20050517-C00155.png)
JP2005505583A5 (US06894165-20050517-C00155.png)
RU2009103300A (ru) Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии
JP2008516959A5 (US06894165-20050517-C00155.png)
JP2005503433A5 (US06894165-20050517-C00155.png)
JP2004525184A5 (US06894165-20050517-C00155.png)